News

Results found (485)
February 14, 2012
Tiltan begins Phase II pancreatic cancer trial

Tiltan Pharma Ltd has begun a Phase II clinical trial of its TL-118 drug for the treatment of pancreatic cancer. The trial will include 80 patients at three Israeli hospitals, and will take about a year.

January 30, 2012
IMMUNE Pharmaceuticals Granted US$1 Million (NIS 3.8M) by the Office of the...

ERZLIYA, Israel and NEW YORK, Jan 30, 2012 (GlobeNewswire via COMTEX) -- IMMUNE Pharmaceuticals, an emerging leader in the development of monoclonal antibody based therapeutics for the treatment of inflammatory diseases and cancer, today...

January 18, 2012
Israeli Team Produces Anti-Malaria Drug From Tobacco Plants

Israeli scientists, led by Hebrew University Professor, Alexander Vainstein, are using genetically modified tobacco to produce the anti-malaria drug artemisinin.

January 10, 2012
“Do I fit?” a system for assessing the degree to which a person fits to...

"Do I Fit?" System was developed by Kivunim team headed by Prof. Itamar Gati, is aimed at assessing the degree to an individual’s career-related preferences fit the core characteristics of an occupation he or she considers. The system currently...

December 22, 2011
Bio-filter blasts nitrates out of the water

Nitrates in drinking water pose serious health problems, but a new low-tech solution from Israel is coming to the rescue.

December 19, 2011
Yissum Presents: Tobacco plant can produce anti-malaria drug

Hebrew University researchers used plan to produce an effective anti-malaria drug; combating malaria is one of the eight Millennium Development Goals.

 

December 19, 2011
Therapeutics co AtoxBio raises $3.25m

Atox Bio will be included as one of the portfolio companies of Integra Holdings, a holding company formed by Yissum, the technology transfer company of the Hebrew University of Jerusalem.

December 11, 2011
Here Come the NanoMABs - A new monoclonal antibody-based drug

A new monoclonal antibody-based drug development company brings a fresh technological approach and ambitious business model to the Israeli biotech scene.

November 15, 2011
Yissum Introduces a Novel, Environmentally-Friendly Biological Solution for...

Technology to be presented today at WATEC, the Water Technologies, Renewable Energy and Environmental Control Exhibition and Conference

November 14, 2011
Drug development co Avraham Pharmaceuticals raises $3m

Avraham Pharmaceuticals has begun a Phase II clinical trials of its treatment, which combines existing drugs from Teva and Novartis. Yissum Technology has announced that its 30% stake in Avraham Pharmaceuticals (after the latest investment) will...

November 2, 2011
Yissum Out-Licenses a Breakthrough Seed Improvement Technology to Morflora

The novel technology has been proven effective in a number of plant species

October 6, 2011
Yissum Signs Master Collaboration Agreements With P&G, General Motors

 

Yissum, the TTO for the Hebrew University of Jerusalem, has inked agreements with Cincinnati-based Procter & Gamble, the world’s largest consumer goods company, and General Motors.